fundament
new
strategi
treatment
infecti
diseas
modul
host
immun
respons
enhanc
clearanc
infecti
agent
reduc
tissu
damag
due
inflamm
antimicrobi
host
defens
peptid
investig
potenti
new
class
antimicrobi
drug
recent
immunomodulatori
activ
begun
appreci
modul
innat
immun
synthet
variant
host
defens
peptid
call
innat
defens
regul
idr
protect
without
direct
antimicrobi
action
discuss
potenti
current
limit
exploit
immunomodulatori
activ
idr
novel
antiinfect
pathway
idr
show
signific
promis
current
research
uncov
mechanist
inform
aid
futur
develop
idr
clinic
use
infecti
diseas
remain
lead
caus
death
major
burden
healthcar
system
worldwid
exampl
hiv
pandem
continu
claim
two
million
live
per
year
estim
million
peopl
live
hivaid
worldwid
novel
human
pathogen
sever
acut
respiratori
syndrom
sar
associ
coronaviru
avian
influenza
recent
emerg
infecti
diseas
includ
tuberculosi
diarrhor
diseas
remain
among
lead
caus
death
danger
also
pose
spread
infecti
agent
new
geograph
locat
exemplifi
recent
case
west
nile
viru
infect
north
america
addit
rapid
evolut
antibiot
resist
mani
bacteri
pathogen
creat
urgent
need
new
antimicrobi
drug
strategi
treatment
infecti
diseas
rapidli
expand
knowledg
immun
system
creat
new
opportun
develop
immunomodulatori
therapi
unlik
convent
antibiot
design
target
pathogen
therapi
exert
protect
effect
act
host
immun
system
mani
therapi
design
target
immun
system
enter
clinic
use
recent
decad
mani
progress
clinic
trial
includ
immunosuppress
therapeut
use
tissu
transplant
autoimmun
inflammatori
condit
compound
design
stimul
immun
respons
exampl
vaccin
adjuv
although
wide
varieti
compound
investig
therapeut
approv
date
belong
one
follow
class
monoclon
antibodi
tolllik
receptor
tlr
ligand
deriv
cytokin
chemokin
small
molecul
monoclon
antibodi
use
clinic
stimul
block
cellsurfac
receptor
inactiv
cytokin
molecul
circul
deliv
antigen
dendrit
cell
direct
toxin
toward
tumor
cell
tlr
ligand
use
immunostimulatori
activ
exampl
ligand
monophosphoryl
lipida
mpl
use
adjuv
vaccin
hepat
b
viru
hbv
human
papillomaviru
hpv
addit
agonist
imiquimod
approv
topic
treatment
hpvinduc
genit
wart
basal
cell
carcinoma
variou
compound
design
stimul
also
undergo
clinic
trial
primarili
adjuv
vaccin
chronic
viral
infect
adjunct
cancer
chemotherapi
immunotherapeut
use
cytokin
chemokin
hormon
exemplifi
typei
interferon
treatment
chronic
hbv
infect
granulocyt
monocytecoloni
stimul
factor
gmcsf
treatment
neutropenia
glucocorticoid
treatment
asthma
chronic
inflammatori
diseas
common
applic
small
molecul
target
intracellular
signal
transduct
pathway
exampl
organ
transplant
reject
limit
inhibit
mammalian
target
rapamycin
mtor
rapamycin
inhibit
calcineurin
cyclosporin
thu
reduc
tcell
signal
transduct
mani
small
molecul
target
compon
pathway
involv
nuclear
factor
kb
nfkb
mitogenactiv
protein
kinas
mapk
janu
kinasesign
transduc
activ
transcript
jakstat
also
undergo
clinic
trial
adopt
transfer
dendrit
cell
autolog
cytotox
tcell
effect
therapi
form
cancer
also
consid
immunotherapi
although
mani
immunotherapi
approv
use
clinic
mani
other
shown
efficaci
clinic
trial
number
obstacl
prevent
widespread
use
use
immunosuppress
therapi
often
associ
increas
risk
infect
might
also
predispos
individu
cancer
immunostimulatori
treatment
result
inflammatori
tissu
damag
autoimmun
potenti
fatal
cytokin
storm
risk
limit
applic
immunotherapi
lifethreaten
condit
bettertoler
treatment
avail
increasingli
recogn
condit
treatabl
gener
stimul
suppress
immun
system
demonstr
failur
immunosuppress
therapi
sepsi
henc
need
develop
tool
precis
control
modul
andor
polar
immun
respons
commerci
viabl
ideal
therapi
also
need
broadspectrum
target
class
relat
condit
pathogen
challeng
highlight
import
studi
immun
system
system
biolog
perspect
predict
outcom
efficaci
immunomodulatori
therapi
discuss
box
host
defens
peptid
multifunct
innat
immun
mediat
host
defens
peptid
hdp
also
known
antimicrobi
peptid
investig
potenti
immunotherapeut
agent
uniqu
combin
immunostimulatori
antiinflammatori
properti
hdp
produc
immun
system
multicellular
organ
extrem
divers
perspect
sequenc
structur
despit
divers
peptid
amphipath
molecul
overal
net
posit
charg
high
content
cation
hydrophob
amino
acid
class
peptid
cathelicidin
defensin
histatin
distinguish
sequenc
structur
mechan
product
gener
characterist
cathelicidin
defensin
describ
box
mammal
peptid
primarili
produc
leukocyt
mucos
epitheli
cell
keratinocyt
mani
hdp
show
broadspectrum
microbicid
activ
either
due
interact
disrupt
microbi
membran
transloc
bacteria
act
intern
target
undoubtedli
play
key
role
immun
defens
within
locat
phagolysosom
leukocyt
crypt
small
intestin
howev
microbicid
activ
peptid
highli
sensit
antagon
dival
cation
serum
anion
macromolecul
glycosaminoglycan
thu
immunomodulatori
activ
probabl
signific
mani
physiolog
environ
immunomodulatori
activ
hdp
includ
divers
effect
box
system
biolog
approach
studi
immunomodulatori
activ
drug
develop
complex
system
innat
immun
system
complex
nonlinear
network
great
potenti
subtl
manipul
signal
pathway
subsequ
chang
cytokin
product
farreach
downstream
effect
might
benefici
complet
predict
desir
control
recent
discuss
schadt
et
al
progress
drug
discoveri
develop
requir
integr
approach
take
account
nonlinear
causal
relationship
inher
complex
system
concept
appli
particularli
immunomodul
signific
crosstalk
pathway
immun
system
possibl
model
entir
innat
immun
system
either
vitro
comput
howev
system
biolog
approach
aid
understand
complex
interact
signal
pathway
attempt
understand
like
effect
immunmodulatori
drug
requir
appreci
associ
interact
within
immun
system
whole
effect
major
system
metabol
hormon
neuron
pathway
comput
aid
system
biolog
approach
mani
freeli
avail
commerci
bioinformat
tool
databas
datamin
analysi
mani
aspect
biolog
system
particular
interest
develop
immunomodulatori
drug
includ
follow
interactom
data
specif
innat
immun
innatedb
wwwinnatedbcom
manual
curat
databas
analysi
platform
gene
protein
interact
pathway
signal
respons
human
mous
innat
immun
respons
immunologyspecif
inform
especi
immunerelev
transcriptom
analysi
innat
immun
databas
http
dbsystemsbiologynetiidb
pathway
interact
data
ncinatur
pathway
interact
databas
http
pidncinihgov
tool
specif
protein
interact
analysi
intact
http
wwwebiacukintact
develop
use
innatedb
integr
data
mani
freeli
avail
databas
manual
curat
interact
inform
analysi
tool
visual
capabl
provid
insight
signal
pathway
potenti
downstream
effect
peptid
treatment
exampl
recent
report
applic
approach
studi
experiment
verif
bioinformat
predict
conceiv
system
could
use
conjunct
gene
array
proteom
data
aid
iter
ration
design
test
immunomodulatori
peptid
analyz
individu
peptid
influenc
differ
pathway
pathway
ontolog
analys
also
implic
specif
biolog
process
activ
peptid
cathelicidin
cation
amphipath
peptid
divers
linear
ahel
bhairpin
structur
produc
proteolysi
cterminu
cathelindomaincontain
protein
precursor
human
one
cathelicidin
precursor
produc
primarili
leukocyt
epitheli
cell
cleav
form
peptid
tissu
rang
shorter
peptid
alter
properti
mice
also
produc
one
cathelicidin
cramp
wherea
cattl
pig
cathelicidin
peptid
famili
highli
divers
defensin
cation
amphipath
peptid
approxim
length
amino
acid
triplestrand
bsheet
structur
contain
three
disulfid
bond
base
pattern
disulfid
bond
defensin
classifi
b
less
common
udefensin
famili
human
adefensin
produc
neutrophil
azurophil
granul
part
antimicrobi
arsen
paneth
cell
intestin
crypt
well
leukocyt
epitheli
cell
wherea
bdefensin
produc
mucos
epithelia
skin
leukocyt
udefensin
circular
peptid
antihiv
activ
produc
human
far
found
old
world
monkey
trend
biotechnolog
cell
migrat
surviv
prolifer
induct
mani
antimicrobi
immun
mediat
target
peptid
activ
includ
leukocyt
mucos
epitheli
cell
keratinocyt
vascular
endotheli
cell
tabl
high
sequenc
divers
multifunct
natur
hdp
provid
mani
opportun
design
artifici
peptid
deriv
therapeut
applic
therapeut
potenti
peptid
direct
antimicrobi
activ
well
studi
sever
peptid
enter
clinic
trial
howev
immunomodulatori
activ
hdp
explor
extent
one
first
synthet
immunomodulatori
peptid
base
hdp
templat
ie
small
bovin
hdp
bactenecin
innat
defens
regul
mediat
vivo
protect
bacteri
challeng
absenc
direct
antimicrobi
activ
propos
mechan
action
involv
enhanc
chemokin
product
accompani
moder
proinflammatori
cytokin
tumor
necrosi
factor
tnfa
mediat
modul
specif
intracellular
signal
pathway
activ
provid
power
rational
use
hdp
design
synthet
peptid
optim
immunomodulatori
activ
diagrammat
overview
current
approach
idr
design
present
figur
import
aspect
design
immunomodulatori
peptid
develop
valid
screen
techniqu
highthroughput
vitro
screen
antibacteri
activ
use
valid
iter
optim
ration
design
antimicrobi
peptid
use
larg
data
set
made
possibl
highthroughput
screen
peptid
librari
possibl
identifi
particular
physic
characterist
correl
well
direct
antimicrobi
activ
contrast
owe
complex
interact
multipl
cell
type
effector
molecul
possibl
screen
subtl
immunomodulatori
activ
vitro
surrog
marker
activ
must
use
instead
necessari
use
screen
correl
enhanc
protect
exampl
select
base
vitro
immunomodulatori
antiendotox
activ
induc
chemokin
product
promot
secret
inhibit
inflammatori
respons
certain
tlr
ligand
neutrophil
defensin
produc
neutrophil
store
within
neutrophil
granul
play
import
microbicid
role
phagolysosom
releas
extracellularli
act
neutrophil
chemoattract
inhibit
neutrophil
apoptosi
reduc
proinflammatori
cytokin
promot
chemokin
induct
antimicrobi
function
neutrophil
mast
cell
mast
cell
import
produc
skin
bdefensin
mast
cell
chemoattract
promot
mast
cell
degranul
convent
dendrit
cell
defensin
cathelicidin
dendrit
cell
dc
chemoattract
promot
differenti
monocytederiv
dc
inhibit
dc
matur
activ
tlrligand
bdefensin
might
promot
dc
activ
endogen
ligand
adjuv
activ
defensin
cathelicidin
vivo
might
mediat
part
activ
dc
plasmacytoid
dendrit
cell
complex
dna
oligonucleotid
strongli
induc
ifna
product
plasmacytoid
dc
activ
might
contribut
patholog
psoriasi
epitheli
cell
keratinocyt
promot
keratinocyt
migrat
product
inhibit
keratinocyt
apoptosi
modul
respons
tlr
ligand
might
wound
heal
activ
skin
alter
proteolyt
process
implic
patholog
rosacea
bronchial
epithelium
act
bronchial
epitheli
cell
stimul
cytokin
chemokin
product
promot
apoptosi
intestin
epithelium
adefensin
produc
paneth
cell
microbiocid
activ
play
import
role
immun
defens
gut
reduc
adefensin
product
might
contribut
crohn
diseas
promot
mucin
product
surviv
intestin
epitheli
cell
cell
vascular
endothelium
induc
activ
prolifer
vascular
endothelium
promot
angiogenesi
mesenchym
stromal
cell
act
chemokin
mesenchym
stromal
cell
promot
product
variou
cytokin
well
vegf
contribut
angiogenesi
tumor
progress
cancer
cell
promot
migrat
prolifer
lung
ovarian
breast
cancer
cell
product
cancer
cell
vivo
promot
tumor
growth
howev
also
augment
anticanc
therapeut
activ
cpg
oligonucleotid
review
trend
biotechnolog
vol
activ
name
enhanc
releas
chemokin
peptidestimul
human
peripher
blood
mononuclear
cell
pbmc
abil
protect
mice
bacteri
infect
anoth
possibl
screen
would
abil
suppress
tnfa
induct
respons
treatment
tlr
agonist
even
use
marker
candid
peptid
must
ultim
test
vivo
isol
cell
system
captur
complex
innat
immun
respons
thu
compar
test
antimicrobi
activ
often
strong
correl
vitro
vivo
activ
much
laborintens
costli
gener
larg
data
set
necessari
applic
comput
method
immunomodulatori
peptid
design
despit
problem
preced
exampl
synthet
endotoxinbind
peptid
optim
protect
vivo
fragment
human
hdp
optim
antiendotoxin
activ
appropri
amino
acid
substitut
gallo
colleagu
subsequ
separ
weak
antimicrobi
immunomodulatori
properti
individu
truncat
peptid
deriv
certain
studi
activ
smaller
bactenecinand
indolicidinlik
synthet
peptid
optim
compon
adjuv
formul
innat
immun
instruct
adapt
immun
screen
chemokineinduc
activ
subject
vivo
analysi
one
challeng
ration
design
idr
identif
specif
interact
partner
date
sever
receptor
identifi
peptid
howev
extracellular
receptor
hdp
known
featur
cellpenetr
peptid
inde
shown
also
taken
figur
design
strategi
idr
design
test
idr
iter
process
initi
candid
peptid
base
natur
occur
hdp
design
use
comput
tool
randomli
gener
candid
peptid
test
vitro
vivo
comput
analysi
use
select
characterist
associ
function
new
candid
peptid
design
use
structurefunct
relationship
inform
test
reveal
inform
data
vitro
vivo
test
also
inform
studi
mechan
action
idr
inform
feed
back
bioinformat
comput
design
approach
structur
diagram
taken
research
collaboratori
structur
bioinformat
rcsb
protein
data
bank
trend
biotechnolog
cell
featur
requir
chemokineinduc
activ
propos
idrlik
peptid
enter
cell
interact
particular
cellular
compon
modul
intracellular
signal
pathway
immun
cell
recent
identifi
two
intracellular
receptor
unpublish
data
ref
suspect
multipl
receptor
hdp
idr
interactor
identifi
peptid
optim
shape
hydrophob
andor
charg
characterist
might
design
dock
studi
although
requir
uptak
might
place
certain
restraint
peptid
design
absenc
inform
iter
optim
via
amino
acid
substitut
screen
would
seem
effect
strategi
anim
model
also
present
challeng
test
immunomodulatori
agent
signific
variat
exist
within
immun
system
differ
mammal
therefor
particular
peptid
highli
protect
mice
might
similarli
effect
human
address
challeng
might
necessari
use
primari
human
cell
eg
pbmc
vitro
studi
demonstr
parallel
data
anim
infect
studi
howev
alway
case
new
drug
efficaci
human
confirm
drug
enter
clinic
trial
safeti
alreadi
demonstr
three
immunomodulatori
cation
peptid
human
clinic
trial
two
origin
develop
antimicrobi
peptid
howev
former
found
safe
deliv
topic
efficaci
phase
ii
clinic
trial
target
inflammatori
sequella
sever
acn
noninfecti
inflammatori
skin
diseas
rosacea
system
safeti
demonstr
immunocompromis
hematopoet
stem
cell
transplant
recipi
anoth
interest
peptid
deriv
heavi
chain
hla
class
molecul
also
safe
clinic
trial
although
much
inform
regard
peptid
publicli
avail
accord
genzym
corpor
http
enhanc
heme
oxygenas
activ
inhibit
inflammatori
respons
stimuli
lipopolysaccharid
lp
phytohemagglutinin
pha
doublestrand
rna
cytokin
tnfa
interleukin
il
reduc
product
proinflammatori
cytokin
tnfa
interferon
ifn
g
affect
product
sever
cytokin
includ
propos
mechan
action
involv
interfer
intracellular
signal
pathway
although
specif
detail
interactor
current
unknown
wherea
cation
peptid
might
modul
innat
immun
respons
inflammatori
stimuli
differ
way
peptid
suppress
induct
certain
proinflammatori
cytokin
tnfa
effect
cytokin
vari
exampl
affect
product
wherea
enhanc
product
distinct
respons
peptid
indic
valu
differ
design
strategi
base
hla
class
molecul
wherea
design
base
bovin
cathelicidin
importantli
rang
potenti
activ
indic
understand
intricaci
immunomodulatori
peptid
interact
host
cell
compon
pathway
might
possibl
design
peptid
custom
immunomodulatori
effect
target
differ
diseas
box
peptid
base
immunotherapi
still
infanc
thu
littl
clinic
experi
lean
must
look
field
immunomodul
gener
clinic
evalu
immunotherapeut
must
approach
manner
differ
tradit
pharmacolog
immun
system
selfamplifi
broadspectrum
antiinfect
exploit
hdp
tend
focu
potenti
use
direct
antibacteri
howev
immunomodulatori
peptid
final
come
age
clinic
candid
approach
potenti
applic
target
infecti
agent
virus
fungi
parasit
direct
action
like
modul
appropri
signal
pathway
regardless
antiinfect
activ
immunomodulatori
peptid
could
also
act
antiinflammatori
drug
mani
seem
moder
proinflammatori
cytokin
tnfa
peptid
list
tabl
consid
treatment
sepsi
chronic
inflammatori
condit
inflammatori
bowel
diseas
addit
hdp
idr
strong
abil
revers
proinflammatori
activ
lp
suggest
potenti
antiendotox
agent
wound
heal
antitumor
activ
promot
wound
heal
independ
direct
antimicrobi
properti
could
potenti
exploit
peptid
mimic
activ
anoth
import
activ
context
abil
stimul
angiogenesi
although
enhanc
potenti
tumor
metastasi
potenti
peptidebas
drug
antitumor
agent
demonstr
current
trial
tabl
strong
data
support
use
synthet
idr
compon
vaccin
formul
inclus
polyllysin
vaccin
formul
cpgoligodinucleotid
odn
moder
induct
potenti
danger
proinflammatori
cytokin
respons
addit
compris
synthet
peptid
klkl
klk
attach
synthet
odn
formul
indolicidin
cpg
odn
polyphosphazen
induc
antigenspecif
cellular
humor
respons
garlapati
et
al
recent
demonstr
adjuv
activ
idr
neonat
pig
combin
molecul
cpg
odn
polyphosphazen
author
propos
formul
could
use
adjuv
effect
neonat
popul
notori
difficult
success
vaccin
highli
suscept
mani
potenti
fatal
infecti
diseas
also
conceiv
peptid
develop
adjuv
mucos
vaccin
could
optim
enhanc
induct
proinflammatori
cytokin
eg
chemokin
show
adjuv
activ
administ
mucos
vaccin
trend
biotechnolog
vol
respons
rapidli
overcom
potenti
infecti
agent
multipli
exponenti
perhap
assum
immunomodulatori
drug
demonstr
typic
doserespons
pharmacodynam
addit
potenti
harm
accompani
inappropri
stimul
immun
dictat
cautiou
approach
immun
respons
often
delic
balanc
upset
balanc
greatli
render
system
unabl
return
homeostasi
minor
perturb
immun
homeostasi
observ
preclin
test
translat
catastroph
effect
human
case
nearleth
cytokin
storm
induc
antagonist
phase
trial
therefor
clinic
trial
immunomodulatori
drug
often
evalu
compound
approach
avoid
excess
respons
system
absorpt
exampl
investig
treatment
ulcer
coliti
structur
modifi
prevent
proteolyt
degrad
system
absorpt
two
phase
ii
trial
combin
cohort
patient
reveal
drug
well
toler
advers
effect
equival
placebo
efficaci
improv
sigmoidoscopi
score
coliti
patient
receiv
medium
high
dose
drug
pathogenesi
ulcer
coliti
thought
least
partial
due
dysregul
host
respons
intestin
microbiota
although
investig
antiinflammatori
properti
might
also
alter
host
respons
microbiota
manner
similar
antiinfect
peptid
sever
peptidebas
drug
immunomodulatori
antimicrobi
activ
enter
clinic
trial
topic
antimicrobi
exhibit
immunomodulatori
gener
antiinflammatori
activ
tabl
advantag
topic
applic
circumvent
need
demonstr
system
safeti
thu
seri
peptid
use
topic
antimicrobi
includ
pexiganan
omiganan
iseganan
tabl
subsequ
investig
reveal
clinic
use
immunomodulatori
activ
reduc
plasma
tnfa
level
anim
sepsi
model
phase
iii
clinic
trial
recent
initi
oral
mucos
patient
receiv
radiat
therapi
neoplast
diseas
drug
explicitli
refer
antimicrobi
http
base
observ
feel
strong
possibl
immunomodulatori
activ
play
substanti
role
clinic
benefit
demonstr
cation
peptid
drug
immunomodulatori
peptid
current
use
antiinfect
agent
drug
glutoxim
although
peptid
quit
differ
cation
idr
describ
tripeptid
deriv
oxid
glutathion
glutoxim
current
prescrib
russia
adjunct
tradit
therapi
treatment
pulmonari
dissemin
mycobacterium
tuberculosi
infect
addit
glutoxim
standard
tuberculosi
therapi
regim
reduc
time
need
clear
bacterium
increas
time
resolut
pulmonari
infiltr
increas
rate
post
infect
weight
gain
advers
effect
limit
transient
febril
event
resolv
discontinu
drug
preclin
studi
human
neutrophil
whole
blood
demonstr
immunomodulatori
mode
action
suggest
immunomodulatori
peptidebas
drug
safe
effect
glutoxim
current
undergo
phase
iii
clinic
trial
usa
chemotherapi
adjuv
http
nonsmallcel
lung
cancer
rather
antiinfect
possibl
rel
low
incid
tuberculosi
usa
lesser
potenti
return
invest
earli
result
promis
includ
reduct
chemotherapyinduc
myelosuppress
modul
lymphocyt
subset
suggest
glutoxim
might
also
immunomodulatori
role
treatment
neoplast
diseas
excit
area
dual
antiinfect
antiinflammatori
action
peptid
immunotherapi
potenti
treatment
bacteremia
septicemia
although
clinic
data
avail
yet
deriv
use
phase
safeti
trial
chemotherapi
patient
febril
neutropenia
http
wwwinimexpharmacom
thu
futur
immunomodulatori
peptid
extrem
promis
drug
candid
issu
potenti
toxic
vivo
stabil
appropri
deliveri
rout
must
overcom
antiinfect
potenti
resist
develop
also
import
clearli
possibl
design
idr
without
substanti
vitro
anim
model
toxic
issu
still
remain
regard
potenti
vivo
toxic
especi
human
multipl
dose
appropri
formul
rout
administr
complet
clinic
safeti
trial
peptidebas
drug
list
tabl
show
least
peptid
administ
safe
via
topic
applic
howev
whether
peptid
safe
deliv
rout
still
open
question
vivo
stabil
proteolyt
process
peptid
also
potenti
concern
although
small
peptid
like
degrad
minut
hour
insid
host
result
indic
treatment
h
prior
h
bacteri
challeng
still
protect
anim
model
rais
question
peptid
presum
degrad
rapidli
longlast
effect
whether
enhanc
peptid
stabil
desir
context
one
possibl
peptid
prime
immun
cell
inde
abil
transloc
immun
cell
might
protect
proteolyt
degrad
consist
observ
peptid
activ
deliv
mani
differ
rout
possibl
indic
local
prime
cell
cell
contain
peptid
migrat
infect
site
one
way
enhanc
stabil
creat
damino
acid
form
peptid
exploit
specif
proteas
lamino
acid
form
threedimension
structur
peptid
like
import
interact
specif
receptor
might
render
peptid
inact
problem
circumv
use
retroinverso
peptid
compris
damino
acid
revers
sequenc
preserv
spatial
posit
side
chain
maintain
proteas
resist
damino
acid
form
cost
manufactur
synthet
peptid
high
strategi
enhanc
bioavail
ie
appropri
formul
also
import
decreas
cost
treatment
one
import
characterist
idr
lower
likelihood
microorgan
develop
resist
case
direct
antimicrobi
innat
immun
system
evolv
alongsid
microb
subtli
augment
respons
enhanc
select
pressur
bacteri
immun
evas
mechan
addit
enhanc
innat
clearanc
microb
mediat
idr
result
creation
bacteri
debri
continu
promot
inflamm
absenc
live
bacteria
provid
yet
anoth
advantag
tradit
antibiot
therapi
inde
peptid
actual
suppress
septic
inflammatori
respons
synthet
immunomodulatori
idr
peptid
signific
potenti
antiinfect
therapeut
current
research
promis
reveal
crucial
mechanist
inform
greatli
enhanc
develop
optim
idr
potenti
tailor
design
idr
differ
purpos
necessarili
antiinfect
abil
subtli
alter
normal
balanc
protect
innat
immun
respons
chemokin
product
concomit
leukocyt
recruit
enhanc
potenti
harm
effect
excess
inflamm
suppress
provid
uniqu
opportun
assist
innat
immun
protect
pathogen
approach
unlik
result
develop
microbi
resist
idr
also
avoid
suppress
inflamm
associ
bacteri
debri
often
accompani
convent
antibiot
therapi
although
much
research
still
requir
area
potenti
novel
approach
antiinfect
therapi
vast
disclosur
statement
rew
hancock
founder
scientif
advisori
board
member
inimex
pharmaceut
inc
sharehold
migenix
inc
